Latest across the states
The newest ibogaine developments from every state, most recent first. Select a state for its full record.
Last checked: October 26, 2026
Texas Ibogaine Research Corporation signs U.S. manufacturing deal
Psyence BioMed's Texas subsidiary agreed with DEA-registered Benuvia Operations of Round Rock, Texas, to manufacture pharmaceutical-grade ibogaine in the U.S. This builds on a September 28 term sheet for an exclusive U.S. ibogaine licence from Psyence Labs, with a definitive agreement due by November 30, 2026. The company runs separately from the state-funded IMPACT trials.
Source: GlobeNewswire (Psyence BioMed)
Psychedelic pilot before conference committee
The House-backed pilot is among the items before the six-member conference committee negotiating the economic development bill.
Source: MASSterList
Psyence BioMed forms Texas Ibogaine Research Corporation
The Nasdaq-listed company set up a Texas-headquartered subsidiary to coordinate U.S. ibogaine supply, licensing, manufacturing and regulatory work. It is weighing a possible Texas ibogaine trial for opioid use disorder, which would depend on protocol, regulatory and funding approvals.
Source: GlobeNewswire (Psyence BioMed)
Barrow and ASU outline the ibogaine brain injury trial
ASU holds a subcontract on the $5 million ADHS grant. The study will enroll 40 people with chronic symptoms from traumatic brain injury.
Source: ASU News
HEAL Act stalls in committee as nonprofits fund their own research
WUNC reports the bill, which would have created a psychedelic research task force and grant fund covering ibogaine, stalled in committee, while nonprofits such as the Pearl Institute in Waynesville raise money for research on their own.
Source: WUNC
KJZZ reports the Barrow award
Public radio coverage of the $5 million grant to Barrow for ibogaine and brain injury.
Source: KJZZ
State-backed research under way through the fund
Axios Indianapolis reports the fund, administered by the Division of Mental Health and Addiction, is backing an Indiana University psilocybin trial for veterans and first responders; the budget adds $300,000 a year for ibogaine research.
Source: Axios Indianapolis
ADHS grant awarded to Barrow Neurological Institute
$5 million for a Phase 1/2 ibogaine trial in neurological disorders such as TBI, with Arizona State University researchers; enrollment expected to start next year.
Source: Barrow Neurological Institute
Psychedelic research funding gains traction with lawmakers
North Carolina Health News reports growing legislative interest in the HEAL Act's research grants, which would cover ibogaine.
Source: North Carolina Health News
HB 1772 signed into law
Governor Kelly Ayotte signed HB 1772 as Chapter 333 of 2026; the law took effect 2026-09-13.
Source: LegiScan
House passes economic development bill with psychedelic pilot
The House adopted, by unanimous amendment, a five-year pilot letting the Department of Public Health permit up to three licensed mental health clinics to offer supervised on-site treatment with naturally occurring psychedelic materials; the bill passed 148-2. Ibogaine is not named; advocates seek its inclusion.
Source: WWLP / State House News Service
SB 43 becomes Act 956 without governor's signature
The Psychedelic-Assisted Therapy Initiative became law without Gov. Landry's signature and took effect 2026-08-01. Louisiana will take part in a national ibogaine research and drug-development consortium.
ASAM state chapter comments on opioid-settlement ibogaine funding
Addiction medicine society commented on legislation allowing opioid settlement dollars to fund ibogaine research.
Source: ASAM
Bipartisan HEAL Act seeks $5.4 million for psychedelic research
SB 1018 would create a research grant fund and task force at NCDHHS for studies of ibogaine, MDMA and psilocybin, focused on veterans and other people living with trauma.
Source: NC Newsline
Addiction medicine society writes to House Rules Committee
The Michigan Society of Addiction Medicine wrote to House Rules Committee members on HB 6020, backing continued research into ibogaine while urging that opioid settlement dollars go to proven measures such as medication for opioid use disorder and naloxone distribution.
Committee sends HB 6020 toward the Rules Committee
The House Families and Veterans Committee took up HB 6020 again on June 9, a week after its testimony hearing, and reported the bill with a recommendation for referral to the Committee on Rules; the House concurred.
Source: Michigan Legislature
Governor signs HB26-1325
Gov. Jared Polis signed HB26-1325, sponsored by Reps. Jarvis Caldwell and Lisa Feret and Sens. Matt Ball and Rod Pelton, creating the ibogaine pilot program. It took effect August 12, 2026.
Source: Office of Governor Jared Polis
Committee discusses HB 6020
Michigan Advance reports the House Families and Veterans Committee discussed Greene's bill, with testimony from ibogaine research proponents.
Source: Michigan Advance
Public comment submitted on HB 6020
Reason Foundation submitted testimony supporting HB 6020 to the House Families and Veterans Committee.
Source: Reason Foundation
State Bar section submits technical input
The State Bar of Michigan's Cannabis Law Section submitted testimony on HB 6020 raising concerns about the bill's scope and its focus on a single compound; the State Bar itself took no position.
Source: State Bar of Michigan
HOPE Treatment Act assigned Public Chapter 1119
HB 2075 and its Senate companion SB 2149 were filed 2026-02-02. The Senate bill carried the act through both chambers and was completed as Public Chapter 1119 on the day of the governor's signature.
Source: Tennessee General Assembly
Governor signs the HOPE Treatment Act
The legislature sent the act to the governor on 2026-05-22 after Senate passage (31-1) on 2026-04-15, House passage (84-1) on 2026-04-22 and Senate concurrence (28-0) on 2026-05-05. The governor signed it on 2026-05-27, and it became Public Chapter 1119.
Source: Tennessee General Assembly
Session adjourns without final passage
SCS HCS HBs 1717 & 1643 was placed on the Senate informal calendar on May 7 and remained there when the legislature adjourned on May 15, so the ibogaine grant program was not enacted.
Source: psilocybinlegalization.com
Conference report adopted
Conference report on HB 1772 adopted; bill also bundles the physician associate licensure compact.
Source: NH General Court
Ohio considers joining other states' psychedelic trials
Ohio Capital Journal reports on lawmakers weighing participation with other states in testing psychedelic-assisted treatments, including ibogaine.
Source: Ohio Capital Journal
Governor signs HB 3834
Gov. Kevin Stitt approved the Oklahoma Breakthrough Therapy Act, sponsored by Rep. Stan May and Sen. Avery Frix. KOSU's weekly politics roundup covered the new ibogaine study law.
Source: KOSU
SB 43 passes both chambers unanimously
Senate 37-0, House 97-0; sent to the governor. Covers ibogaine and psilocybin research pathways.
Source: WAFB
HB 2817 returned to Formal Perfection Calendar
HB 2817 was placed back on the House Formal Perfection Calendar.
Source: Missouri House
Study committee hears policy and stakeholder testimony
The Ibogaine Treatment Study Committee met at the Ohio Statehouse with an agenda of policy and stakeholder testimony.
Legislature passes HB26-1325
Passed both chambers with bipartisan support; up to five pilot sites, FDA IND support, benefit-sharing plan with iboga-growing communities in Africa.
Source: Vicente LLP
Bipartisan sponsors announce plan
Reps. Greene and McFall introduced HB 6020 in May 2026 as a plan to make Michigan a leader in ibogaine health research, directing $50 million from the Opioid Healing and Recovery Fund to FDA-overseen trials.
Source: Michigan House Republicans
SB 3199 task force bill in conference
SB 3199 would create a two-year Mental Health Emerging Therapies Task Force at JABSOM; a tracker showed Failed at 2026-04-29 while another source showed House passage. Final outcome unverified.
Source: Hawaii State Legislature
S1817 reported from committee
The Senate Standing Committee on Alcoholism and Substance Use Disorder reported S1817, which was committed to the Finance Committee.
Source: NY State Senate
Governor vetoes SB 77; veto overridden
Veto issued 2026-04-13; override completed and bill delivered to Secretary of State 2026-04-14.
Source: Kentucky Legislature
HB 1477 marked dead
A bill tracker shows HB 1477 as dead after the 2026 session; no enactment found.
Source: PolicyRisk
Vermont Public covers ibogaine interest
Vermont Edition segment on ibogaine, featuring Rep. Brian Cina's bill to use opioid settlement funding for ibogaine research and Dr. Rick Barnett, former chair of Vermont's psychedelic advisory group.
Source: Vermont Public
SB 77 passes General Assembly
Senate Republicans' release says SB 77 establishes an ibogaine research framework and heads to the governor.
Source: Kentucky Senate Republicans
HB 1296 dies in Senate committee at sine die
The bill stayed in the Senate Health and Human Services Committee when the General Assembly adjourned, ending the 2025-26 session.
Source: LegiScan
House passes combined psilocybin and ibogaine research bill 137-11
The House sent HCS HBs 1717 & 1643 to the Senate 137-11 after amending it to include ibogaine alongside a supervised psilocybin study for veterans and first responders.
Source: Missouri Independent
2026 supplemental budget keeps the ibogaine study proviso
The 2026 supplemental operating budget (ESSB 5998, Chapter 268, Laws of 2026, effective 2026-04-01) amends the University of Washington section and carries the $10,000 ibogaine cohort-study proviso forward unchanged; that section was outside the governor's partial-veto items.
Source: Washington State Legislature (ESSB 5998 session law)
Governor vetoes 12 bills including HB 4626
Gov. Morrisey said the state should support medical innovation 'without requiring the state to award grants of undefined and unfunded amounts.' The vetoes were announced 2026-04-02.
Source: WV Public Broadcasting
Legislature passes HOPE Act
Framework for ibogaine trials with drug developers, institutions and hospitals; matching funds and safety protocols required.
Source: Hoodline
State proceeds without a drug company
Proposals from drug companies did not meet statute (FDA plan, Texas presence, $50 million match, 20% of future revenue); Rep. Harris called it the first major step toward FDA approval.
Source: KSAT
Governor approves HB 314
Ibogaine Drug Development Clinical Trial Act approved; consortium coordinates with a lead consortium, FDA and other states from 2026-07-01; 20% of IP revenue to General Fund.
Bill sent to Gov. Reeves
Legislators sent the bill to fund ibogaine trials with up to $5 million of opioid settlement money.
Source: Mississippi Today
Committee advances psychedelic pilot bills
Joint Committee on Mental Health, Substance Use and Recovery advanced H.4200 and H.2203 to Health Care Financing; ibogaine discussed as a possible substance under H.4200.
HB 4626 passes
Ibogaine drug development trial grant program passes; sponsors include Delegates Browning and Worrell.
Source: West Virginia Legislature
HB 4110 left in committee at adjournment
After a 2026-02-10 public hearing the bill did not advance and is recorded as failed.
Source: LegiScan
HB 1296 passes Georgia House
Breakthrough Treatments for Georgia Heroes pilot; ibogaine-based therapies listed among eligible treatments. Sent to Senate 2026-03-06.
Source: Georgia General Assembly
HCS for HBs 2817 and 2961 reported Do Pass
Committee substitute reported Do Pass after an 8-1-2 vote on 2026-02-25.
Source: LegiScan
How this tracker is kept
- Each state is checked against legislature records, agency releases and published reporting, and carries the date it was last checked. Every development links to its source.
- “No known activity” means the state was checked on the date shown and no ibogaine-specific law, bill, funding or task force was found.
- The directory lists organizations and public offices with their own websites. Listing points readers to them and does not endorse them.
- This tracker is offered for education and does not constitute legal or medical advice. Ibogaine and iboga remain Schedule I substances under federal law. See the medical disclaimer.
- To share a development or request a correction, write to aloha@vitalkauai.com. For daily coverage, see Iboga Worldwide.